2020 China International Biopharma4.0 Summit
2020中国国际生物制药4.0峰会
Feb,13th-14th,2020 | Shanghai China
2020年2月13日-14日 | 中国上海
会议概述
20204.0CIBP
Overview of 2020CIBP Summit
Based on the transformation &upgrading and policy reform of China’s pharmaceutical industry, and theprevious successful experience of last session, China International Biopharma4.0 Summit(2020) will further deepen topics concerning the implementation of specific policies and regulations on the biological cell culture technology, protein characterization and optimization and ICH-Q series, and discuss more practical topics such as Pharma 4.0, the latest progress in technologies, future trends, digitization and intelligence of biopharma companies, CGMP quality management system from laboratories to plants, regulations on the use of SUS, optimization of cell culture technology, advanced experience of upstream and downstream biopharma technology, and outsourcing technology development IP. The summit will also provide an optimal platform for you to communicate with government officials, CMO, CRO, biopharma companies, pharmaceutical device providers, software and logistics solutions providers, industry leaders and experts on international projects.
了解更多
Gathering of global giants
500+ Delegates from BioPharma Industry.
250+ Global Biopharma Delegates
30+ Famous Experts
Gathering of industrial pioneers
30+ Worldwide Biopharma Solution Providers
50+ Media Exposure
2020:CIBP4.0
Feb. 13th -14th , 2020 | Shanghai, China
International Biopharma 4.0 Summit 2020
会议概述
Introduction of some
Speakers
This summit provides a platform for participating representativesto have high-level dialogues. The representatives reached a cooperation intention on long-term projects on the site through in-depth exchange with high-level management of all enterprises and effective interaction between upstream and downstream industrial chain, which lent a splendid color to the summit. Most representatives were satisfied with the summit and expressed their expectation on the next session.

Dr.Jason Li

COO/SVP
Trinomab Biotech Co. Ltd.

Jianfeng Gao

Sr.Director QA
Innovent Biologics

Jens Ewert

Partner,China Life Science & Healthcare Leader
Deloitte

Ranjan Chakrabarti, Ph.D.

Vice President - Global Biologics
United States Pharmacopeial Convention

Xun Liu

VP
Jiangsu Hengrui Medicine Co.,Ltd

Stefan Kappeler

Technology Manager Life Sciences
Exyte

Jimmy Li

Vice President
WuXi Biologics

Jizu Yi

Vice President of CMC Process
Wuhan YZY Biopharma Co. Ltd

Dr. Joe Zhou

President/Principal Scientist
Genor Biopharma Co.,Ltd

Werner Blersch

Global Product Manager
Uhlmann

Juan Hernandez Bort, PhD

Associate Director,Head of Gene Therapy Technologies
Takeda

Prof. Xianbao Zhan

GI Oncology Expert
Changhai Hospital

Otmane Boussif

Global Head Cell & Gene Therapy Technical Development
Novartis

Dr. Zhiwei Song

Senior Principal Scientist
Bioprocessing Technology Institute A*STAR, Singapore

John Zhang

Vice President,Process Development & Manufacturing Technology
BeiGene Co., Ltd.

Dr.Xingyu Zhong

Senior Application Specialist of Single Cell Multiomics Platform
BD (China)

Dr. Alexey Rak

Head of Bio Structure and Biophysics
Sanofi

Denis Kole

Manager Continuous Bioprocessing
Pall Biotech

Tony Au

General Manager,China
AbbVie

Anthony Mire-Sluis

Head of Global Quality
AstraZeneca

Joan Shen MD, PhD

Vice President of Research and Clinical Development
I-Mab Biopharma Co., Ltd

Jianxin Yang MD, PhD

Chief Medical Officer,SVP, Clinical Development and Regulatory Affair
CStone Pharmaceuticals

Dr. Chengbing Wu

Founder & CEO
EpimAb Biotherapeutics Inc.

Matthias Maaz

Global business Director for Life Sciences and Specialty Chemicals
Honeywell

Zhengyu Yi

Executive Vice President and Secretary-General
Shanghai Pharmaceutical Profession Association

Junli Zhang

Senior Vice President and Senior Advisor to CEO
Shanghai Henlius Biotech Co.,Ltd.

Zhuanglin Li

Vice President
RemeGen, Ltd

Judie Liu

Deputy General Manager, BioPharma
Qilu Pharmaceutical Co. Ltd.

James Weidner

Executive Director of Process Development
Amgen

Youling Wu, PhD

Chairman and President
Zhejiang Teruisi Pharmaceutical Co., Ltd

James Yan,PhD

Executive Vice President, Head of Pre-Clinical Development and Program & Portfolio Management
Zai Lab

Cuihua Liu,PhD

SVP,Technology &Development
Bio-Thera Solutions, Ltd.

Cynthia Pussinen

Vice President/General Manager of Pharma and Life Sciences business
Honeywell

Xinan Lu, PhD

Co-Founder,CMO
Beijing Immunochina Pharmaceuticals Co., Ltd

Michael Xie, PhD

Vice President
Shanghai Henlius Biotech Co.,Ltd.

Fred Mao

Partner,Managing Director
Frost & Sullivan

Wenzhi Tian,PhD

Chairman, President and Chief Executive Officer
ImmuneOnco Biopharma

Jerry Yang, PhD

General Manager
HJB

Alan Wong

Vice President of Biomanufacturing
WuXi Biologics

Sponsors

Organiser:Borscon

Borscon Group